Sign in
Taking people in United StatesEarly phase 1

MRI with contrast liquid to stage bladder cancer before surgery

Tests a bladder MRI with contrast liquid in adults with bladder cancer.

Key facts

Who runs it
Jodi Maranchie
Where
Pittsburgh, United StatesSee the site
Trial code
Registry title
Virtual Histology of the Bladder Wall for Bladder Cancer Staging
Status
Recruiting
Phase
Early phase 1
People taking part
42 people, planned
Started
23 May 2025
Expected to end
30 Dec 2028
Type of study
Interventional
Treatments tested
  • Magnetic Resonance Imaging
  • Gadobutrol intravesical administration (4mM)
  • Ferumoxytol intravesical administration (5 mM)
Record updated
17 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a bladder tumor seen at cystoscopy and scheduled for tumor removal, or with muscle-invasive bladder cancer that can be removed by surgery. It tests a new MRI scan of the bladder wall.

Age
18 to 90 years
Sex
All sexes can join.
Disease stage
A papillary bladder tumor found at cystoscopy and scheduled for removal through the urethra (TURBT), or proven muscle-invasive bladder cancer that is in one place and can be removed by surgery meant to remove all of the disease.
Biomarker or test result
Normal kidney function: creatinine under 1.5 x the upper limit of normal, or creatinine clearance of 50 mL/min/1.73 m2 or more. ECOG performance status of 0 or 1.

Main reasons for not taking part

  • Severe allergic reaction to gadobutrol or ferumoxytol
  • Severe fear of enclosed spaces that prevents finishing the MRI
  • Implanted device, prosthesis or pacemaker that cannot go into an MRI
  • Known or suspected cancer spread to other parts of the body
  • Pregnancy, breastfeeding or plans to conceive

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • 18 to 90 years of age
  • Able to understand and willing to sign a written informed consent document
  • A papillary tumor identified by cystoscopy that has been scheduled for TURBT OR histologically proven MIBC that is clinically localized and amenable to surgical resection with curative intent
  • Performance status of ECOG 0 or 1
  • Normal renal function as defined as creatinine less than 1.5 x institutional upper limit of normal (ULN) OR creatinine clearance greater than or equal to 50 mL/min/1.73 m2 by Cockcroft-Gault formula for subjects with creatinine levels greater than or equal to 1.5 x ULN

Who cannot take part

  • Severe hypersensitivity reaction to gadobutrol or ferumoxytol
  • Known or suspected metastatic disease
  • Untreated urinary tract infection
  • Known urethral stricture disease that would prohibit placement of foley catheter
  • Any other conditions considered as unacceptable risk by the treating physician
  • Severe claustrophobia that will prevent completion of the MRI study
  • Any MRI-non-compatible implanted device, prosthetic or pacemaker
  • Women with active pregnancy, lactation or plans to conceive

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

Where in United States

  • UPMC Hillman Cancer Center - Dept of UrologyPittsburgh, United StatesContact: Brieanna HC Marino, MSTaking people

About the trial

What the trial wants to find out

This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21 subjects) or prior to radical cystectomy for muscle invasive disease (21 subjects). Subjects will undergo a single MRI study: a pre-contrast, single breath hold image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and then a second, post-contrast image. Images will be reviewed by two dedicated abdominal radiologists, who are blinded to the pathologic staging, for determination of tumor presence and depth of bladder wall penetration.

The group in the trial

  • Magnetic Resonance ImagingTreatment being tested

    Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumoxytol (5 mM) and a second, single breath hold post-contrast image.

    Treatment: Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), and Ferumoxytol intravesical administration (5 mM)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Virtual Histology of the Bladder Wall for Bladder Cancer Staging; A Novel Intravesical Contrast-Enhanced MRI for Bladder Cancer Staging
Plain-language title
MRI with contrast liquid to stage bladder cancer before surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04369560, who can take part
Record updated
17 December 2025